TY - JOUR
T1 - Preliminary data on COVID-19 in patients with hemoglobinopathies
T2 - A multicentre ICET-A study
AU - de Sanctis, Vincenzo
AU - Canatan, Duran
AU - Corrons, Joan Lluis Vives
AU - Karimi, Mehran
AU - Daar, Shahina
AU - Kattamis, Christos
AU - Soliman, Ashraf T.
AU - Wali, Yasser
AU - Alkindi, Salam
AU - Huseynov, Valeh
AU - Nasibova, Afag
AU - Tiryaki, Tarık Onur
AU - Evim, Melike Sezgin
AU - Gunes, Adalet Meral
AU - Karakas, Zeynep
AU - Christou, Soteroula
AU - Campisi, Saveria
AU - Zarei, Tahereh
AU - Khater, Doaa
AU - Oymak, Yesim
AU - Kaleva, Valeriya
AU - Stoyanova, Denka
AU - Banchev, Atanas
AU - Galati, Maria Concetta
AU - Yassin, Mohamed A.
AU - Kakar, Shruti
AU - Skafida, Myrto
AU - Kilinc, Yurdanur
AU - Alyaarubi, Saif
AU - Verdiyevas, Narmin
AU - Stoeva, Iva
AU - Raiola, Giuseppe
AU - Mariannis, Demetris
AU - Ruggiero, Leopoldo
AU - Di Maio, Salvatore
N1 - Publisher Copyright:
© 2020 American Society for Microbiology. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Objectives: This study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent β thalassemia major (TM), β-thalassemia intermedia (TI) and sickle cell disease (SCD). Design: A total of 17 Centers, from 10 countries, following 9,499 patients with hemoglobinopathies, participated in the survey. Main outcome data: Clinical, laboratory, and radiologic findings and outcomes of patients with COVID-19 were collected from medical records and summarized. Results: A total of 13 patients, 7 with TM, 3 with TI, and 3 with SCD, with confirmed COVID-19, were identified in 6 Centers from different countries. The overall mean age of patients was 33.7±12.3 years (range:13-66); 9/13 (69.2%) patients were females. Six patients had pneumonia, and 4 needed oxygen therapy. Increased C-reactive protein (6/10), high serum lactate dehydrogenase (LDH; 6/10), and erythrocyte sedimentation rate (ESR; 6/10) were the most common laboratory findings. 6/10 patients had an exacerbation of anemia (2 with SCD). In the majority of patients, the course of COVID-19 was moderate (6/10) and severe in 3/10 patients. A 30-year-old female with TM, developed a critical SARS-CoV-2 infection, followed by death in an Intensive Care Unit. In one Center (Oman), the majority of suspected cases were observed in patients with SCD between the age of 21 and 40 years. A rapid clinical improvement of tachypnea/dyspnea and oxygen saturation was observed, after red blood cell exchange transfusion, in a young girl with SCD and worsening of anemia (Hb level from 9.2 g/dl to 6.1g/dl). Conclusions: The data presented in this survey permit an early assessment of the clinical characteristics of COVID 19 in different countries. 70% of symptomatic patients with COVID-19 required hospitalization. The presence of associated co-morbidities can aggravate the severity of COVID- 19, leading to a poorer prognosis irrespective of age.
AB - Objectives: This study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent β thalassemia major (TM), β-thalassemia intermedia (TI) and sickle cell disease (SCD). Design: A total of 17 Centers, from 10 countries, following 9,499 patients with hemoglobinopathies, participated in the survey. Main outcome data: Clinical, laboratory, and radiologic findings and outcomes of patients with COVID-19 were collected from medical records and summarized. Results: A total of 13 patients, 7 with TM, 3 with TI, and 3 with SCD, with confirmed COVID-19, were identified in 6 Centers from different countries. The overall mean age of patients was 33.7±12.3 years (range:13-66); 9/13 (69.2%) patients were females. Six patients had pneumonia, and 4 needed oxygen therapy. Increased C-reactive protein (6/10), high serum lactate dehydrogenase (LDH; 6/10), and erythrocyte sedimentation rate (ESR; 6/10) were the most common laboratory findings. 6/10 patients had an exacerbation of anemia (2 with SCD). In the majority of patients, the course of COVID-19 was moderate (6/10) and severe in 3/10 patients. A 30-year-old female with TM, developed a critical SARS-CoV-2 infection, followed by death in an Intensive Care Unit. In one Center (Oman), the majority of suspected cases were observed in patients with SCD between the age of 21 and 40 years. A rapid clinical improvement of tachypnea/dyspnea and oxygen saturation was observed, after red blood cell exchange transfusion, in a young girl with SCD and worsening of anemia (Hb level from 9.2 g/dl to 6.1g/dl). Conclusions: The data presented in this survey permit an early assessment of the clinical characteristics of COVID 19 in different countries. 70% of symptomatic patients with COVID-19 required hospitalization. The presence of associated co-morbidities can aggravate the severity of COVID- 19, leading to a poorer prognosis irrespective of age.
KW - COVID-19
KW - Clinical course
KW - Patients' characteristics
KW - Risk factors
KW - SARS-CoV-2
KW - Sickle cell disease
KW - β-thalassemia
UR - http://www.scopus.com/inward/record.url?scp=85090438053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090438053&partnerID=8YFLogxK
U2 - 10.4084/MJHID.2020.046
DO - 10.4084/MJHID.2020.046
M3 - Article
C2 - 32670524
AN - SCOPUS:85090438053
SN - 2035-3006
VL - 12
JO - Mediterranean Journal of Hematology and Infectious Diseases
JF - Mediterranean Journal of Hematology and Infectious Diseases
IS - 1
M1 - e2020046
ER -
